---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Perspective and time frame"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Perspective and time frame. Topics: Perspective recommended for budget impact analysis, Perspective and time horizon of a published budget impact model of nadofaragene firadenovec, Perspective and time horizon of the ICER review, and Perspectives and time horizons of other published analyses. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/perspective-and-time-frame"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Perspective and time frame

<a id="heading-4.2.2"></a>

## 4.2.2 Perspective and Time Frame

<a id="topic-4.2.2-1"></a>

### Budget impact model of cretostimogene grenadenorepvec: perspective and time frame

No evidence found.

<a id="topic-4.2.2-2"></a>

### Perspective recommended for budget impact analysis

> “The Task Force recommends that the budget impact of a new health technology should consider the perspective of the specific health-care decision-maker.”

Source: [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)

> “In either case, the BIA should use data that reflect values specific to a particular decision maker's population.”

Source: [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)

<a id="topic-4.2.2-3"></a>

### Perspective and time horizon of a published budget impact model of nadofaragene firadenovec

> “The analysis was conducted from the perspective of a US third-party payer, simulating a hypothetical healthcare plan with one million covered lives over a 3-year horizon following the market entry of nadofaragene firadenovec”
> “All costs were estimated in 2024 US dollars (USD)”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.2.2-4"></a>

### Perspective and time horizon of the ICER review

> “All costs were undiscounted and estimated over a five-year time horizon, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with the new therapy.”
> “The base case used a US health care sector perspective.”
> “The decision model was evaluated over a lifetime time horizon with three-month cycles.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.2.2-5"></a>

### Perspectives and time horizons of other published analyses

> “Cost-effectiveness was evaluated over a 5-year period using a willingness-to-pay threshold of $100,000 per quality-adjusted life-year from the US Medicare perspective.”
> “Cycle length was set at 3 months with the model terminating after 20 cycles, representing a 5-year time horizon.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

> “Costs were evaluated over a 15-month time horizon, which was selected to account for the timing of initial response assessment at 3 months and the 12-month DOR.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

> “We developed a Markov cohort simulation model with a 3-month cycle length and lifetime horizon to estimate the total costs, QALYs, and cost per additional QALY from the health sector perspective.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
